At a virtual community event, Penn Memory Center (PMC) Co-Directors David Wolk, MD, and Jason Karlawish, MD, provided patients and families with an update on anti-amyloid treatments for Alzheimer’s disease and the plans for accessing these drugs through Penn Medicine.
Drs. Wolk and Karlawish reviewed the risks and benefits Leqembi (lecanemab), which recently received full approval from the Food and Drug Administration (FDA), and donanemab, a drug similar to lecanemab that is expected to get FDA approval at the end of 2023.
The co-directors said Penn Medicine and PMC have developed a workflow to rollout Leqembi and future drugs to PMC patients. This workflow will be piloted before becoming more widely available to patients.